Vulvovaginal Candidiasis (VVC) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Vulvovaginal Candidiasis (VVC) occurs when Candida species superficially penetrate the mucosal lining of the vagina and cause an inflammatory response. The dominant inflammatory cells are typically polymorphonuclear cells and macrophages. Patients may present with discharge, which is usually thick and adherent, excoriations, external dysuria, vaginal itching, vaginal burning, dyspareunia, or swelling. Risk factors for acute candidal vulvovaginitis include estrogen use, elevated endogenous estrogens, diabetes mellitus, immunosuppression, and broad-spectrum antibiotic use. Although candidal vulvovaginitis is more common in sexually active women, there is no evidence that candidal infection is sexually transmitted. Patients with recurrent candidal vulvovaginitis have predisposing genetic factors that cause them to be susceptible to recurrent fungal infections. These factors may also predispose to hypersensitivity to Candida. The most common responsible pathogen is C. Albicans (in about 90% of cases), with most remaining instances caused by Candida glabrata.

 

Around 1 million outpatient visits to treat vaginal candidiasis, amongst which ~8% to 10% of patients reported recurrent candidal vulvovaginitis.

 

The competitive landscape of Vulvovaginal Candidiasis (VVC) includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Vulvovaginal Candidiasis (VVC) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Vulvovaginal Candidiasis (VVC) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Vulvovaginal Candidiasis (VVC) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          Ibrexafungerp   Scynexis, Inc.   Phase 3

2          Prof-001           ProFem GmbH  Phase 2

3          Venus 20          EMS     Phase 2

4          SHR8008 capsule         Jiangsu HengRui Medicine Co., Ltd.            Phase 3

5          Miconazole Nitrate 2% + Domiphen Bromide       Aesculape CRO Belgium BV Phase 2

6          Oteseconazole (VT-1161)          Mycovia Pharmaceuticals Inc.            Phase 3

7          VT-1161           Viamet  Phase 2

8          NDV-3A            NovaDigm Therapeutics, Inc.     Phase 1

9          Lcr Regenerans Probionov         Phase 3

10        MAT2203 and MAT2501            Matinas BioPharma Nanotechnologies, Inc. Phase 2

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more